How to appeal an Elevance Health bone marrow transplant (allogeneic hsct) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Elevance Health-specific note: Operates Anthem BCBS in 14 states. Owns Carelon (formerly AIM) which manages utilization for specialty drugs and advanced imaging. State complaint route is to the state insurance department where the policy was issued.

What Elevance Health's policy requires for bone marrow transplant (allogeneic hsct)

Cited policy: BCBS Niktimvo (Axatilimab-csfr) for Chronic GVHD

Adult and pediatric ≥6 yo with chronic GVHD after ≥2 prior systemic therapies. NIH consensus criteria for cGVHD. Hematologist-oncologist Rx. 0.3 mg/kg IV q2wk. Reauth at 12-24 weeks with NIH symptom-organ improvement.

How Elevance Health denies bone marrow transplant (allogeneic hsct) — and how to counter it

Where Elevance Health pushes back: 1) Niktimvo experimental; 2) Try Rezurock or Imbruvica first if not tried; 3) ≥4 prior lines required (vs ≥2 per FDA); 4) Cost.

Counter-arguments that hold up: Niktimvo (axatilimab-csfr) FDA Aug 14, 2024 for cGVHD after ≥2 prior systemic therapies — NOT experimental. AGAVE-201 (Wolff NEJM 2024) — ORR ~74% with durable responses; well-tolerated. Distinct anti-CSF1R mechanism vs Jakafi (JAK1/2) and Rezurock (ROCK2) — sequencing or prior failure of one does not preclude others. NCCN-endorsed and ASTCT/EBMT updated guidance includes Niktimvo as 3L+ option. ≥2 prior systemic per FDA label, NOT ≥4.

What Elevance Health typically denies for bone marrow transplant (allogeneic hsct)

Across Elevance Health's commercial and Medicare books, denials cluster around a small number of patterns. For bone marrow transplant (allogeneic hsct), expect:

• Step therapy
• Medical necessity for biologics
• Out-of-network for behavioral health
• Bariatric surgery prior auth

Treatments most often denied in this category

These are the bone marrow transplant (allogeneic hsct) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Allo-HSCT (MAC)
• Allo-HSCT (RIC)
• Allo-HSCT (NMA)
• MRD allo-HSCT
• MUD allo-HSCT
• Haplo allo-HSCT

How to submit the appeal to Elevance Health

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Elevance Health cited in the denial.
3. File the appeal through Elevance Health's portal (members: https://www.anthem.com ; providers: https://providers.anthem.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In IN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Elevance Health's prior-authorization criteria by drug: Elevance Health PA criteria on ApprovalHelp.